Printer Friendly

Bavarian Nordic's ongoing phase 2 trial evaluating BN-Brachyury in chordoma shows positive results.

NORDIC BUSINESS REPORT-June 6, 2019-Bavarian Nordic's ongoing phase 2 trial evaluating BN-Brachyury in chordoma shows positive results

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Bavarian Nordic A/S (CPH:BAVA) (OTC: BVNRY), a biotechnology company focused on the development of innovative therapies against cancer and infectious diseases, announced on Wednesday the confirmation by the Data and Safety Monitoring Board (DSMB) of a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint.

Reportedly, as this meets the initial pre-defined threshold of activity for the first stage of the phase 2 trial, recruitment will be expanded to enrol another 19 patients, while the first 10 patients continue to be treated and evaluated.

According to the company, the proof-of-concept phase 2 trial was designed to determine if the combination of BN-Brachyury and radiation therapy, the current standard of care, results in a clinically meaningful objective response rate (ORR), measured as a percentage of patients with a decrease in tumour size within 12 months of radiation therapy. This is a timeframe during which historical controls show an ORR of less than 5% with radiation alone.

The first stage of the study enrolled 10 patients between November 2018 and January 2019. This study will now advance into stage 2, expanding enrolment to a total of 29 patients with an overall goal of achieving four patients with objective responses, corresponding to an ORR of ~14% for all patients enrolled for the study to be considered successful.

Chordoma is a rare cancer that universally over expresses brachyury and occurs in the base of the skull and spine.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Date:Jun 6, 2019
Words:288
Previous Article:Clas Ohlson's profit down in 2018/19.
Next Article:Securitas' board resolves on purchase of own series B shares.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters